Class / Patent application number | Description | Number of patent applications / Date published |
514404000 | Divalent chalcogen or acyclic nitrogen double bonded directly to ring carbon of the diazole ring, or tautomeric equivalent | 49 |
20080207722 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders - The present invention is related to the use of a Glepp-1 inhibitor for the manufacture of a medicament for the treatment of an autoimmune and/or an inflammatory disorder. | 08-28-2008 |
20080214640 | Thrombopoietin mimetics - Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative. | 09-04-2008 |
20080234346 | PYRAZALIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS - The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors. | 09-25-2008 |
20080262068 | Method of Tonic Treatment With Oxyphenbutazone Derivatives - The present invention provides a method of tonic treatment of an aging mammalian subject, or a subject suffering from mild inflammation, lupus, fatigue, lethargy or the aftereffects of infection, disease or treatment, comprising administration of a compound of formula (I) or a salt thereof. Said compounds are also used as a support to another drug and/or treatment regime especially a method for the treatment of a viral, autoimmune, hyperplastic or neoplastic disease, and for the prevention of diseases associated with old age including arthritis (especially RA), Alzheimer's, Parkinson's and Huntington's diseases, cancer or other neoplastic disease. | 10-23-2008 |
20080306130 | Inhibitors of ubiquitin E1 - The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention. | 12-11-2008 |
20090012143 | CHEMICAL COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF - Disclosed are compounds of formula (I) or pesticidally acceptable salts thereof wherein, for example, W is ═CR | 01-08-2009 |
20090076112 | DEUTERIUM-ENRICHED ELTROMBOPAG - The present application describes deuterium-enriched eltrombopag, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090131496 | PYRAZOLONE DERIVATIVE EMULSION FORMULATIONS - Pyrazolone derivative emulsion formulations are provided. The emulsion formulations include a pyrazolone derivative active agent, e.g., Edaravone, oil, water and an emulsifier. Also provided are methods of making and using the subject emulsion formulations. | 05-21-2009 |
20090143453 | METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES - Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal. | 06-04-2009 |
20090291995 | 3'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-Y- LIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID BIS-(MONOETHANOLAMINE) - An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid. | 11-26-2009 |
20100063124 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM - The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine. | 03-11-2010 |
20100130577 | PYRAZALONE DERIVATIVE FORMULATIONS - Pyrazolone derivative formulations are provided. The formulations include a pyrazolone derivative active agent, e.g., edaravone, and an amphiphilic solubilizing agent. Also provided are methods of making and using the subject formulations. | 05-27-2010 |
20100298398 | THROMBOPOIETIN RECEPTOR AGONIST (TPORA) KILLS ACUTE HUMAN MYELOID LEUKEMIA CELLS - The present invention provides methods of inhibiting human myeloid leukemia cell growth and proliferation by administering a thrombopoietin receptor agonist (TpoRA), a derivative, or variant thereof, to an individual with AML. | 11-25-2010 |
20100305180 | INHIBITORS OF UBIQUITIN E1 - The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention. | 12-02-2010 |
20110003873 | PHARMACEUTICAL COMPOSITION AND ITS USE IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF CEREBROVASCULAR DISEASES - A pharmaceutical composition comprises 3-methyl-1-phenyl-2-pyrazolin-5-one and borneol, and can be used to prepare the medicine for treating cerebrovascular diseases. | 01-06-2011 |
20110021591 | PHENYLBUTAZONE CARRIER FORMULATION SHOWING INCREASED BIOACTIVITY IN ANIMALS - An improved phenylbutazone carrier composition provides increased palatability to horses. Additionally, the composition improves the bioavailability of the phenylbutazone and thus increases the horse's blood plasma levels of the medicine for the same effective dosage of the medicine. | 01-27-2011 |
20110196008 | POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF - New polymorphs of Eltrombopag and Eltrombopag ethanolamine salt have been obtained and characterized. These polymorphs and pharmaceutical compositions comprising them are useful, for example, in treating conditions leading to thrombocytopenia. | 08-11-2011 |
20110288141 | LOCAL TOPICAL ADMINISTRATION FORMULATIONS CONTAINING FIPRONIL - The present invention provides formulations and methods useful in eradicating ectoparasites on a domestic animal, decreasing the number of ectoparasites on a domestic animal, and/or preventing ectoparasite infestation on a domestic animal, using a local topical formulation comprising fiproniland a veterinarily acceptable carrier. | 11-24-2011 |
20120022124 | POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF - New polymorphs of Eltrombopag and Eltrombopag ethanolamine salt have been obtained and characterized. These polymorphs and pharmaceutical compositions comprising them are useful, for example, in treating conditions leading to thrombocytopenia. | 01-26-2012 |
20120149749 | METHOD OF TREATING THROMBOCYTOPENIA - Invented is a method of treating thrombocytopenia in a human in need thereof which comprises the administration of a therapeutically effective amount of a 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid to such human. | 06-14-2012 |
20120238612 | POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF - New polymorphs of Eltrombopag and Eltrombopag ethanolamine salt have been obtained and characterized. These polymorphs and pharmaceutical compositions comprising them are useful, for example, in treating conditions leading to thrombocytopenia. | 09-20-2012 |
20120277278 | PHENYLBUTAZONE CARRIER FORMULATION SHOWING INCREASED BIOACTIVITY IN ANIMALS - An improved phenylbutazone carrier composition provides increased palatability to horses. Additionally, the composition improves the bioavailability of the phenylbutazone and thus increases the horse's blood plasma levels of the medicine for the same effective dosage of the medicine. | 11-01-2012 |
20120283305 | CYSTEINE PROTEASE INHIBITORS - Compounds of the formula I | 11-08-2012 |
20120289569 | INHIBITORS OF UBIQUITIN E1 - The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention. | 11-15-2012 |
20120309806 | Process for the Sulfinylation of a Pyrazole Derivative - The present invention relates to a process for the of a pyrazole derivative, characterized in that 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carbonitrile (II) is reacted with a sulfinylating agent selected from trifluoromethylsulfinic acid, trifluoromethylsulfinic acid anhydride, and a trifluoromethylsulfinate alkaline or alkaline earth metal salt and mixtures of the acid and/or the salt(s), in the presence of at least one amine acid complex wherein the amine(s) are selected from tertiary amines and the acid(s) are selected from hydrofluoric, hydrochloric, hydrobromic and hydroiodic acid and sulfonic acid derivatives, and with the addition of a halogenating agent. | 12-06-2012 |
20130046004 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to compounds of the formula I, wherein A, D, E, G, R | 02-21-2013 |
20130116294 | PESTICIDAL COMPOSITION AND ITS USE - A composition comprising a carboxamide compound represented by following formula (I), wherein R | 05-09-2013 |
20130203831 | NON PEPTIDIC 14-3-3 INHIBITORS AND THE USE THEREOF - The present invention refers to compounds with inhibitory activity against 14-3-3 proteins and their use in the treatment of tumors, in particular chronic myeloid leukemia. The invention also provides methods for the identification of 14-3-3 protein inhibitors. | 08-08-2013 |
20130261161 | ANTIPARASITIC FORMULATIONS - Fipronil co-formulations are provided herein. The formulations comprise an organic solvent, an alcohol co-solvent, and one or more antioxidants. The formulations provided herein are antiparasitic, and can be used, for example, to combat dog and cat parasites, such as, fleas and ticks. | 10-03-2013 |
20130261162 | PARASITICIDAL FORMULATION - The present invention provides a parasiticidal formulation comprising: Fipronil, or a veterinarily acceptable derivative thereof; at least one C | 10-03-2013 |
20130274307 | COMPOSITIONS COMPRISING ABSCISIC ACID AND A FUNGICIDALLY ACTIVE COMPOUND - The present invention relates to methods comprising applying to a useful plant, the locus thereof or propagation material thereof a combination of abscisic acid and a fungicidally active compound, which fungicidally active compound is a succinate dehydrogenase inhibitor, in particular for increasing the potency of a fungicidally active compound. The invention also relates to compositions comprising abscisic acid and the fungicidally active compounds as well as seeds comprising the combinations. | 10-17-2013 |
20130303581 | POLYMORPHISM IN 5-AMINO-1-(2,6-DICHLORO-4-TRIFLUOROMETHYLPHENYL)-3-CYANO-4-TRIFLUORO METHYL SULFINYL PYRAZOLE - The present invention provides novel crystalline polymorphic forms of fipronil and processes for preparing the same. The present invention also provides a pesticidal composition containing a pesticidally effective amount of a crystalline form of fipronil and a method for controlling pests using a pesticidally effective amount of a crystalline form of fipronil or its composition. | 11-14-2013 |
20140039026 | POLYMORPHS AND AMORPHOUS FORMS OF 5-AMINO-1-[2,6-DICHLORO-4-(TRIFLUOROMETHYL)PHENYL]-4-[(TRIFLUOROMETHYL)SU- LFINYL]-1H-PYRAZOLE-3-CARBONITRILE - The present invention relates to novel crystalline polymorphs, solvate pseudomorphs and amorphous form of 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile (fipronil). The present invention also provides methods for preparing the novel polymorphs, pseudomorphs and amorphous form, as well as insecticidal or pesticidal compositions comprising same, and methods of use thereof as pesticidal agents. | 02-06-2014 |
20140142155 | METHOD OF TREATING THROMBOCYTOPENIA - Invented is a method of treating thrombocytopenia in a human in need thereof which comprises the administration of a therapeutically effective amount of a 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid to such human. | 05-22-2014 |
20140235688 | TREATMENT OF EXTERNAL PARASITES BY ORAL ADMINISTRATION OF PARASITICIDAL AGENTS - Pharmaceutically acceptable compositions of fipronil for oral delivery to mammals and methods for use of the compositions to control external parasites, such as fleas and ticks. | 08-21-2014 |
20140357686 | METHOD OF TREATING DISEASE BY AURICULAR ANESTHESIA OF CRANIAL NERVES - Methods for treating a variety of diseases that comprises performing auricular anesthesia of the vagus, facial, trigeminal, or glossopharyngeal nerves, or combinations thereof. A pharmaceutical composition is administered to an ear canal of a subject in need of such treatment, the composition including an analgesic and an anesthetic. Compositions useful in the taught methods are also provided. | 12-04-2014 |
20140357687 | Pyrazol-3-ones That Activate Pro-apoptotic BAX - This application features pyrazol-3-one compounds that activate pro-apoptotic BAX. Also featured are methods of using such compounds, e.g., for the treatment or prevention of diseases, disorders, and conditions associated with deregulated apoptosis of cells (e.g., insufficient apoptosis of diseased or damaged cells or essentially the absence of apoptosis of diseased or damaged cells). | 12-04-2014 |
20150291519 | CONTROLLED HNO RELEASE THROUGH INTRAMOLECULAR CYCLIZATION-ELIMINATION - Protected HNO donors designed to undergo non-enzymatic release at neutral pH via an intramolecular cyclization-elimination are disclosed. The rate of cyclization, and therefore HNO release, can be controlled by substituents and chain length. Thus, biologically useful HNO donors having tunable HNO release rates are provided. | 10-15-2015 |
20150366209 | PESTICIDAL COMPOSITION IN THE FORM OF AQUEOUS EMULSION - A pesticidal composition is provided in the form of an aqueous emulsion, containing: (a) an agriculturally active ingredient in which a retention rate is less than 50% after irradiation with xenon light (290 nm cutoff) at an intensity of 0.68 W/m | 12-24-2015 |
20160000068 | AQUEOUS SUSPENSION AGROCHEMICAL COMPOSITION - An aqueous suspension agrochemical composition is provided containing fenpyrazamine and an acid component. The composition has no problem of emission of odor and has excellent storage stability. The composition has a pH at 25° C. in a range of 2.5 to 6.5. | 01-07-2016 |
20160000069 | AGROCHEMICAL SOLID FORMULATION - An agrochemical solid formulation contains fenpyrazamine and an acid component. The formulation has no problem of emission of odor and has excellent storage stability. A mixture of 1 g of the agrochemical solid formulation and 99 g of ion exchange water has a pH at 25° C. of 8 or less. | 01-07-2016 |
20160031822 | 3'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-Y- LIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID BIS-(MONOETHANOLAMINE) - Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same. | 02-04-2016 |
20160083353 | SMALL-MOLECULE INHIBITORS TARGETING G-PROTEIN-COUPLED RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS - Provided are inhibitors of Rho GTPase activation, and, in particular, compounds that inhibit RhoA activation by an RhoGEF. Also provided are related pharmaceutical compositions and methods. Also provided are methods of inhibiting Rho GTPase activation. Also provided are methods of screening for compounds that inhibit Rho GTPase activation by a RhoGEF. | 03-24-2016 |
20160143883 | METHOD OF TREATING THROMBOCYTOPENIA - Invented is a method of treating thrombocytopenia in a human in need thereof which comprises the administration of a therapeutically effective amount of a 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid to such human. | 05-26-2016 |
514405000 | Polycyclo ring system having the diazole ring as one of the cyclos | 5 |
20080214641 | Chemical compounds 572 - Compounds of formula (I): | 09-04-2008 |
20080234347 | METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN - The present invention is directed to a method for treating, ameliorating or preventing CB2 receptor mediated pain in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula (I): | 09-25-2008 |
20080234348 | 3-Oxoindazolesquaric Acid Derivatives - Novel squaric acid compounds of the formula (I), in which R | 09-25-2008 |
20080287516 | Phenyl-Substituted Pyrrolidones - The present invention relates to phenyl-substituted pyrrolidones and compounds related to phenyl-substituted pyrrolidones. One use of these compounds is for the inhibition of viruses, e.g., HIV. The invention further relates to methods of malting these compounds, methods of identifying the efficacy of these compounds, and methods of using these compounds to inhibit or prevent HIV infection and related disease states such as AIDS. | 11-20-2008 |
20090036508 | AMINO INDAZOLE DERIVATIVES - Compounds of the formula I | 02-05-2009 |